240 related articles for article (PubMed ID: 28602840)
1. Rational selection of broadly cross-reactive family 2 PspA molecules for inclusion in chimeric pneumococcal vaccines.
Converso TR; Goulart C; Rodriguez D; Darrieux M; Leite LCC
Microb Pathog; 2017 Aug; 109():233-238. PubMed ID: 28602840
[TBL] [Abstract][Full Text] [Related]
2. Selection of family 1 PspA molecules capable of inducing broad-ranging cross-reactivity by complement deposition and opsonophagocytosis by murine peritoneal cells.
Goulart C; Darrieux M; Rodriguez D; Pimenta FC; Brandileone MC; de Andrade AL; Leite LC
Vaccine; 2011 Feb; 29(8):1634-42. PubMed ID: 21211592
[TBL] [Abstract][Full Text] [Related]
3. Recognition of pneumococcal isolates by antisera raised against PspA fragments from different clades.
Darrieux M; Moreno AT; Ferreira DM; Pimenta FC; de Andrade ALSS; Lopes APY; Leite LCC; Miyaji EN
J Med Microbiol; 2008 Mar; 57(Pt 3):273-278. PubMed ID: 18287288
[TBL] [Abstract][Full Text] [Related]
4. Analysis of serum cross-reactivity and cross-protection elicited by immunization with DNA vaccines against Streptococcus pneumoniae expressing PspA fragments from different clades.
Miyaji EN; Ferreira DM; Lopes AP; Brandileone MC; Dias WO; Leite LC
Infect Immun; 2002 Sep; 70(9):5086-90. PubMed ID: 12183557
[TBL] [Abstract][Full Text] [Related]
5. Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments.
Lu J; Sun T; Wang D; Dong Y; Xu M; Hou H; Kong FT; Liang C; Gu T; Chen P; Sun S; Lv X; Jiang C; Kong W; Wu Y
Immunol Invest; 2015; 44(5):482-96. PubMed ID: 26107747
[TBL] [Abstract][Full Text] [Related]
6. Conjugation of PspA4Pro with Capsular Streptococcus pneumoniae Polysaccharide Serotype 14 Does Not Reduce the Induction of Cross-Reactive Antibodies.
da Silva MA; Converso TR; Gonçalves VM; Leite LCC; Tanizaki MM; Barazzone GC
Clin Vaccine Immunol; 2017 Aug; 24(8):. PubMed ID: 28637805
[TBL] [Abstract][Full Text] [Related]
7. Protective properties of a fusion pneumococcal surface protein A (PspA) vaccine against pneumococcal challenge by five different PspA clades in mice.
Piao Z; Akeda Y; Takeuchi D; Ishii KJ; Ubukata K; Briles DE; Tomono K; Oishi K
Vaccine; 2014 Sep; 32(43):5607-13. PubMed ID: 25132335
[TBL] [Abstract][Full Text] [Related]
8. Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection.
Moreno AT; Oliveira ML; Ferreira DM; Ho PL; Darrieux M; Leite LC; Ferreira JM; Pimenta FC; Andrade AL; Miyaji EN
Clin Vaccine Immunol; 2010 Mar; 17(3):439-46. PubMed ID: 20089795
[TBL] [Abstract][Full Text] [Related]
9. Relationship between surface accessibility for PpmA, PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniae.
Gor DO; Ding X; Briles DE; Jacobs MR; Greenspan NS
Infect Immun; 2005 Mar; 73(3):1304-12. PubMed ID: 15731027
[TBL] [Abstract][Full Text] [Related]
10. Development of a conjugate vaccine against invasive pneumococcal disease based on capsular polysaccharides coupled with PspA/family 1 protein of Streptococcus pneumoniae.
Lin H; Peng Y; Lin Z; Zhang S; Guo Y
Microb Pathog; 2015; 83-84():35-40. PubMed ID: 25959527
[TBL] [Abstract][Full Text] [Related]
11. PspA family fusion proteins delivered by attenuated Salmonella enterica serovar Typhimurium extend and enhance protection against Streptococcus pneumoniae.
Xin W; Li Y; Mo H; Roland KL; Curtiss R
Infect Immun; 2009 Oct; 77(10):4518-28. PubMed ID: 19687204
[TBL] [Abstract][Full Text] [Related]
12. A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella Typhi.
Kothari N; Kothari S; Choi YJ; Dey A; Briles DE; Rhee DK; Carbis R
Vaccine; 2015 Feb; 33(6):783-8. PubMed ID: 25545593
[TBL] [Abstract][Full Text] [Related]
13. Protective efficacy of PspA (pneumococcal surface protein A)-based DNA vaccines: contribution of both humoral and cellular immune responses.
Miyaji EN; Dias WO; Tanizaki MM; Leite LC
FEMS Immunol Med Microbiol; 2003 Jun; 37(1):53-7. PubMed ID: 12770760
[TBL] [Abstract][Full Text] [Related]
14. Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A.
Langermann S; Palaszynski SR; Burlein JE; Koenig S; Hanson MS; Briles DE; Stover CK
J Exp Med; 1994 Dec; 180(6):2277-86. PubMed ID: 7964500
[TBL] [Abstract][Full Text] [Related]
15. Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice.
Oliveira ML; Miyaji EN; Ferreira DM; Moreno AT; Ferreira PC; Lima FA; Santos FL; Sakauchi MA; Takata CS; Higashi HG; Raw I; Kubrusly FS; Ho PL
PLoS One; 2010 May; 5(5):e10863. PubMed ID: 20523738
[TBL] [Abstract][Full Text] [Related]
16. Enhanced protective immunity against pneumococcal infection with PspA DNA and protein.
Moore QC; Bosarge JR; Quin LR; McDaniel LS
Vaccine; 2006 Jul; 24(29-30):5755-61. PubMed ID: 16759765
[TBL] [Abstract][Full Text] [Related]
17. Mapping of epitopes recognized by antibodies induced by immunization of mice with PspA and PspC.
Vadesilho CF; Ferreira DM; Gordon SB; Briles DE; Moreno AT; Oliveira ML; Ho PL; Miyaji EN
Clin Vaccine Immunol; 2014 Jul; 21(7):940-8. PubMed ID: 24807052
[TBL] [Abstract][Full Text] [Related]
18. A pneumococcal vaccine combination with two proteins containing PspA families 1 and 2 can potentially protect against a wide range of Streptococcus pneumoniae strains.
Yu J; Chen X; Li B; Gu T; Meng X; Kong W; Wu Y
Immunol Res; 2018 Aug; 66(4):528-536. PubMed ID: 30128745
[TBL] [Abstract][Full Text] [Related]
19. A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA).
Genschmer KR; Accavitti-Loper MA; Briles DE
Vaccine; 2013 Dec; 32(1):39-47. PubMed ID: 24211169
[TBL] [Abstract][Full Text] [Related]
20. Broad protective immune responses elicited by bacterium-like particle-based intranasal pneumococcal particle vaccine displaying PspA2 and PspA4 fragments.
Lu J; Guo J; Wang D; Yu J; Gu T; Jiang C; Kong W; Wu Y
Hum Vaccin Immunother; 2019; 15(2):371-380. PubMed ID: 30235046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
